Study Finds Widening Disparities in Weight-Loss GLP-1 Access
Prescription fills for semaglutide and tirzepatide grew overall between 2021 and 2025, but gaps widened across race, age, and neighborhood income.
Prescription Rates Grew Unevenly Between 2021 and 2025
Prescription fill rates for glucagon-like peptide-1 (GLP-1) receptor agonists grew significantly among commercially insured adults with overweight or obesity, but disparities in access widened over the same period. A study led by researchers at the Boston University School of Public Health (BUSPH) and published in Health Affairs Scholar tracked medical claims data for 512,389 eligible patients without type 2 diabetes between 2021 and 2025.
The overall share of eligible patients who filled a prescription for semaglutide or tirzepatide within six months of qualifying rose from 1.9% in 2021 to 16.6% in 2025. The Food and Drug Administration (FDA) approved semaglutide for chronic weight management in 2021 and tirzepatide for the same indication in 2023. Disparities in who received these medications widened sharply in 2024 and 2025.
The medications mimic a natural hormone that helps regulate insulin, blood sugar, appetite, and digestion. Despite clinical qualifications, large segments of eligible individuals faced persistent obstacles to filling these treatments.
Demographic and Geographic Gaps in Medication Access
Prescriptions for semaglutide and tirzepatide were distributed unevenly across demographic groups and practice locations. The observational analysis revealed that fill rates remained lower among several distinct patient categories:
Patients whose health care provider practiced in an area with lower socioeconomic status (SES), measured by educational attainment in the provider ZIP code, filled prescriptions at lower rates. Prescriptions were also lower among patients in lower body mass index (BMI) categories.
- Men filled prescriptions at lower rates than women.
- Black and Hispanic patients filled prescriptions at lower rates than white patients.
- Younger adults ages 18 to 34 and older adults ages 55 to 64 had lower fill rates than patients ages 35 to 54.
Insurance Hurdles Limit Coverage for Obesity
Insurance benefit design remains a primary factor behind the uneven uptake of GLP-1 therapies for chronic weight management. The study authors noted that patients with type 2 diabetes receive coverage for these medications far more readily than individuals seeking treatment for overweight or obesity alone.
Insurers and health systems often treat obesity as an elective condition rather than an indication requiring pharmacotherapy. This divergence leaves many commercially insured patients without affordable coverage options, even when they meet clinical criteria for treatment.
The authors emphasized that health care providers need structured training on prescribing options, while commercial health plans require benefit adjustments to prevent treatment disparities from compounding existing metabolic health inequities.
Study Design and Cohort Limitations
The study relied on closed medical claims from a commercial database representing more than 175 million individuals. Because the researchers restricted the sample to commercially insured individuals aged 18 to 64, the findings cannot be generalized to all populations.
The analysis did not evaluate patients enrolled in Medicare or Medicaid programs. Individuals without health insurance were excluded, and prescriptions obtained through out-of-pocket, direct-to-consumer digital clinics were not captured in the claims data.
Patients navigating metabolic health decisions should talk to their clinician about insurance coverage policies, prior authorization rules, and alternative clinical pathways.
What to Look For in a Body-Composition Scale
A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.


Related Articles
Type 1 Diabetes Score Misses Remissions in Youth with Obesity
A Diabetes Care study finds insulin dose-adjusted hemoglobin A1c (IDAA1c) misses over half of...
Read article MetabolismGlucose-Powered Implant Improves Blood Sugar in Animal Study
A study in Nature reports on NeuroAxis, an experimental implant powered by glucose that...
Read article MetabolismNatural Peptide Protects Retinal Cells in Laboratory Diabetes Model
A study in Biomedicine & Pharmacotherapy shows the Annexin A1 peptide Ac2-26 shields retinal...
Read article MetabolismGenetic Markers of Young-Onset Type 2 Diabetes Identified in Study
A genome-wide study identified three genetic markers of young-onset type 2 diabetes that impair...
Read articleWant medical weight loss instead of another diet?
Opt Health prescribes and monitors GLP-1 therapy against real labs — insulin, A1C, lipids, thyroid, hormones — so the plan fits your physiology rather than a generic protocol. Medication ships to your door.
See Opt Health's weight-loss program →Topic updates
Get the weekly metabolic health roundup
Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.
Understand Your Health Better
Our free assessment maps your symptoms to the most relevant guides, tools, and product recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Affiliate disclosure: The Metabolic Journal is reader-supported. Some links above are affiliate or referral links and we may earn a commission at no extra cost to you. Products are chosen on the merits; commissions never influence what we recommend. This is general information, not medical advice — talk to your clinician before acting.